Enzo Biochem, Inc. (ENZ) Director Gregory M. Bortz Sells 42,005 Shares
Enzo Biochem, Inc. (NYSE:ENZ) Director Gregory M. Bortz sold 42,005 shares of Enzo Biochem stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $9.82, for a total transaction of $412,489.10. Following the sale, the director now owns 292,875 shares of the company’s stock, valued at $2,876,032.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
COPYRIGHT VIOLATION WARNING: “Enzo Biochem, Inc. (ENZ) Director Gregory M. Bortz Sells 42,005 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/02/enzo-biochem-inc-enz-director-gregory-m-bortz-sells-42005-shares.html.
A number of hedge funds have recently added to or reduced their stakes in the business. IndexIQ Advisors LLC lifted its position in Enzo Biochem by 83.0% in the 3rd quarter. IndexIQ Advisors LLC now owns 103,551 shares of the medical research company’s stock worth $1,084,000 after buying an additional 46,975 shares in the last quarter. CAPROCK Group Inc. acquired a new position in shares of Enzo Biochem during the 3rd quarter worth $118,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Enzo Biochem during the 2nd quarter worth $208,000. The Manufacturers Life Insurance Company increased its stake in shares of Enzo Biochem by 6.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,404 shares of the medical research company’s stock worth $380,000 after purchasing an additional 2,074 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Enzo Biochem during the 2nd quarter worth $124,000. Institutional investors own 62.07% of the company’s stock.
Several research analysts recently issued reports on ENZ shares. BidaskClub upgraded Enzo Biochem from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research cut shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, TheStreet cut shares of Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.
About Enzo Biochem
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.